Medical Health & Life Science Research News

Discover the market report on neuroblastoma pipeline in H1 2017

Neuroblastoma pipeline (Oncology) guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

- Agency -.

Neuroblastoma - Pipeline Review, H1 2017, provides an overview of the Neuroblastoma (Oncology) pipeline landscape.

Key players of Neuroblastoma Pipeline Ability Pharmaceuticals SL, Actuate Therapeutics Inc, Advanced Accelerator Applications SA, Alissa Pharma, Ampio Pharmaceuticals Inc, APAvadis Biotechnologies Srl, APEIRON Biologics AG, AstraZeneca Plc, Bayer AG, Bellicum Pharmaceuticals Inc, Bexion Pharmaceuticals LLC, BioLineRx Ltd, Biotec Pharmacon ASA, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cancer Prevention Pharmaceuticals Inc, Cebiotex SL, Celgene Corp, Celldex Therapeutics Inc, Cielo Therapeutics Inc, Cleveland BioLabs Inc, CorMedix Inc, Curis Inc, Cyclacel Pharmaceuticals Inc, DEKK-TEC Inc, EnGeneIC Ltd

Access Complete Report On Neuroblastoma Pipeline Review H1 2017: http://www.reportsnreports.com/purchase.aspx?name=1057907 .

Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body.

- Agency -.

The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include lump in abdomen or chest, weakness, bone pain, breathing problems, dark circles around the eyes and difficulty in movement.

The condition may be diagnosed by X-ray imaging, CT scan, MRI, biopsy, urine test,. It may be controlled by chemotherapy, radiation therapy, stem cell transplants and medication such as monoclonal antibody regimens.

Get Neuroblastoma Pipeline Review Report 2017@ www.reportsnreports.com/contacts/discount.aspx?name=1057907

Neuroblastoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Neuroblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 20, 19, 1, 44, 5 and 1 respectively.

Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 6, 13 and 3 molecules, respectively.

Neuroblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

News From

ReportsnReports - Industry Trends & ForecastsReportsnReports
Category: Market Research Publishers and RetailersCompany profile: ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision-making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets.